<DOC>
	<DOCNO>NCT02888964</DOCNO>
	<brief_summary>This project Phase II clinical trial aim evaluate efficacy tolerance combination pioglitazone ( Actos® ) imatinib mesylate ( STI571 , CGP57148 , Gleevec® ) patient Chronic Myelogenous Leukemia ( CML ) stable major molecular response ( i.e . BCRABL/ABL ratio assess RTQ-PCR equal low 0.1 % accord European Leukemia Net recommendation ) least 2 year therapy imatinib . Imatinib mesylate ( Gleevec® ) gold standard treatment CML chronic phase ( O Brian et al . 2003 , Druker et al . 2006 ) . Despite high efficacy drug , CML eradicate imatinib alone almost patient . Treatment discontinuation patient treat imatinib complete molecular remission 2 year yield molecular relapse within 6 month half patient , indicate persistence CML progenitor cell . STAT5 expression require CML stem cell engraftment expansion mouse model . STAT5 target dysregulated activity BCR-ABL CML . Recently , Stephane Prost et al . demonstrate PPAR-γ negative regulator STAT5A STAT5B gene expression . Data obtain suggest PPAR-γ agonist may potential therapeutic value reverse myeloproliferative disorder . On basis preclinical study , go ahead administer pioglitazone one patient suffer diabetes type II CML residual disease continuous treatment Gleevec . The amount BCR-ABL transcript detect QPCR decrease dramatically first 3 month combine ( Gleevec + ACTOS ) therapy become undetectable thereafter 9 month post-treatment , late time point assess . This striking anecdotal result form rationale file formal Phase II clinical trial application .</brief_summary>
	<brief_title>Pioglityazone Imatinib CML Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>1 . Patient age 18y 2 . Signed informed consent 3 . Patient Philadelphia chromosome positive chronic phase CML M BCRABL transcript positivity 4 . Treatment imatinib 2 year 5 . No dose modification imatinib within last 3 month 6 . Complete cytogenetic response last cytogenetic analysis within last 12 month 7 . Major molecular remission without complete molecular remission 8 . ECOG grade 0 2 9 . SGOT et SGPT ≤ 2.5 N 10 . Bilirubin serum ≤ 1.5 N 11 . Women childbearing potential ( WOCBP ) must use adequate method contraception 1 . Participation another clinical trial investigative drug within 30 day prior study enrollment 2 . Prior history hematopoietic stem cell transplantation ( autologous allogenic ) 3 . Patient require antidiabetic medication 4 . Cardiovascular disease : Stage I IV congestive heart failure ( CHF ) determine New York Heart Association ( NYHA ) classification system heart failure Myocardial infarction within previous 6 month Symptomatic cardiac arrhythmia require treatment 5 . Grade III IV fluid retention 6 . Known osteoporosis therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>